Immunogen shares rise on lung cancer drug data
Shares in ImmunoGen Inc. (NASDAQ: IMGN) rose 3 percent Thursday morning, after the biotechnology company released positive early data, testing one of its drug candidates against small-cell lung cancer. The Phase 1 study, including 33 patients, showed that 10 patients had a partial response to the drug, and the remainder had “disease control," meaning that the disease did not progress.
The Phase 1 data clears the way for a Phase 2 study, using the Waltham, Mass-based biotech company’s drug candidate, called IMGN901 in combination with two other drugs already on the market. The Phase 2 study is seeking to enroll 120 patients.